Symic Bio, Inc.
Industry
- Biotechnology
- Large Molecule
- Pharmaceuticals
Other Names/Subsidiaries
- Symic Biomedical Inc.
Latest on Symic Bio, Inc.
The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer
The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer
The progression of investigational products through a series of increasingly more sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for c
GlaxoSmithKline PLC 's former CEO, Sir Andrew Witty , has been appointed to G1 Therapeutics Inc. 's board of directors. Witty is chancellor of the University of Nottingham and retired from GSK